ClinicalTrials.gg
RecruitingNCT04853758ANSWER-HFUpdated Apr 4, 2024

Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.

A Phase 3 interventional study of Sacubitril / Valsartan Oral Tablet [Entresto] and Enalapril in Chagas Cardiomyopathy, sponsored by University of Sao Paulo General Hospital. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by University of Sao Paulo General Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Chagas Cardiomyopathy with a site in Brazil — 2 open to participants now, 2 under way, 1 of them phase 3. Chagas Cardiomyopathy · Brazil.

Planned enrollment
2nd of 11
200 · median 42
Started
2021
with 1 other
Phase 3
3 of 14
1 open now
Registered
12th of 14
by date
Lead sponsor
2 of 14
University of Sao Paulo General Hospital

Among the 14 studies in Chagas Cardiomyopathy with a site in Brazil, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2021, is one of 3 in phase 3, and was the 12th registered.

Chagas Cardiomyopathy

17 studies on the registry are indexed under Chagas Cardiomyopathy; 2 are open to participants now.

Browse Chagas Cardiomyopathy studies →

Open to participants now

2 of the 14 studies in Chagas Cardiomyopathy with a site in Brazil are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 2 Chagas Cardiomyopathy studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Chagas Cardiomyopathy with a site in Brazil, or all of them as a file.
02

Study summary

Chagas disease is considered by the World Health Organization (WHO) as one of the most neglected tropical diseases in the world, having relevance in many Latin America countries. In addition, it already affects North America, Europe, Asia and Oceania. Some studies suggest that chagasic heart failure has a worse prognosis, with up to 50% shorter survival than other etiologies. The PARADIGM-HF (Prospective Comparison of Angiotensin Receptor Blocker-Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) study showed 20% reduction in mortality comparing sacubitril/valsartan with the standard treatment with ACE (angiotensin converting enzyme) inhibitors. In the scenario of chagasic cardiomyopathy, a post hoc analysis of PARADGIM-HF was reported on 113 patients. Reduced risk of cardiovascular death or hospitalization for HF was noted in the group treated with sacubitril/valsartan. Attention was drawn the study's limitations that included the small number of patients and reduced statistical power. Therefore, the benefit of this new class remains uncertain in heart failure due to Chagas cardiomyopathy. The ANSWER-HF Trial will be a clinical, randomized, single-center, prospective, double-blind, controlled study. It will include 200 consecutive participants with Chagas cardiomyopathy and left ventricular ejection fraction less than 40% randomized independently. The objective of this study is to evaluate the benefit of sacubitril/valsartan compared with enalapril in patients with heart failure due to Chagas cardiomyopathy, with reduced ejection fraction. The primary endpoint of the study is the change of left ventricular ejection fraction determined by transthoracic echocardiography. Secondary endpoints include: assessment of ventricular arrhythmias; evaluation of functional class; assessment of functional capacity; assessment of ventricular remodeling; and evaluation of biomarkers. The patients will be followed for 6 months after treatment start. All patients will be undergone to Doppler Echocardiography, 24-hour Holter, 6-minute walk test, Biochemical and hematological exams and Biomarkers at the baseline and after 6 months.

Read the detailed description

Introduction: Chagas disease (CD) is an infectious parasitic disease caused by the protozoan Trypanosoma cruzi. It is considered by the World Health Organization (WHO) as one of the most neglected tropical diseases in the world, having relevance in many Latin America countries. In addition, it already affects North America, Europe, Asia and Oceania due to current migration patterns. In the chronic phase, about 70% of individuals have no symptoms and routine complementary examinations related to the heart and digestive system do not show any changes. The other 30% of patients can develop the cardiac and/or digestive form of which about 10% may progress to severe heart disease. Chagasic cardiomyopathy is associated with major heart failure, sudden death, often due to severe arrhythmias and thromboembolic phenomena. This cardiomyopathy has a higher degree of myocardial fibrosis compared with any other etiology. Furthermore, some studies suggest that chagasic heart failure has a worse prognosis, with up to 50% shorter survival than survival with other etiologies, such as ischemic disease and idiopathic dilated cardiomyopathy. The pharmacological treatment of heart failure in Chagas disease comprises neurohormone blockers as is the case for angiotensin II converting enzime (ACE) inhibitors, angiotensin II (AII) receptor blocker (ARBs), beta-blockers and mineralocorticoid antagonists. In 2014 with the publication of the PARADIGM-HF study, a new drug class (ARNI: angiotensin receptor-neprilisin inhibitor) was proposed showing a 20% reduction in mortality compared with the standard treatment with ACE inhibitors. Sacubitril/valsartan is the first molecule of this class. This new molecule acts by blocking AII AT1 (angiotensin type 1) receptors, and therefore, attenuating the harmful effects of this peptide. It also promotes the blocking of the degradation of natriuretic peptides, increasing the protective effects of this family of proteins. In the scenario of chagasic cardiomyopathy, a post hoc analysis of PARADGIM-HF was conducted by Ramires and colleagues who reported on 113 patients treated with sacubitril/valsartan or enalapril. Reduced risk of cardiovascular death or hospitalization for HF was noted in the group treated with sacubitril/valsartan. Attention was drawn the study's limitations that included the small number of patients and reduced statistical power. Therefore, the benefit of this new class remains uncertain in heart failure due to Chagas cardiomyopathy. Knowing that chagasic cardiomyopathy is characterized by intense myocardial fibrosis, inflammation and oxidative stress, and with sacubitril/valsartan being the molecule that has a protective effect in exactly these same mechanisms, our hypothesis is that this drug may improve myocardial remodeling, and therefore it may modulate ventricular function, arrhythmias and functional capacity.

Methods: The ANSWER-HF Trial will be a clinical, randomized, single-center, prospective, double-blind, controlled study. It will include 200 consecutive participants randomized independently. The objective of this study is to evaluate the benefit of sacubitril/valsartan compared with enalapril in patients with heart failure due to Chagas cardiomyopathy, with reduced ejection fraction. Endpoints: The primary endpoint of the study is the change of left ventricular ejection fraction (LVEF) determined by transthoracic echocardiography. Secondary endpoints include: assessment of ventricular arrhythmias; evaluation of functional class; assessment of functional capacity; assessment of ventricular remodeling; and evaluation of biomarkers. Security outcomes include systolic blood pressure (SBP) less than 95 mmHg; renal function assessed by GFR (glomerular filtration rate) less than 30 mL/min; serum potassium > 5.2 mmol/L; and angioedema; whereas, exploratory outcomes are hospitalization for heart failure and mortality from all causes. Randomization: Randomization will be carried out using a RedCap platform blinded randomization being performed 1:1 for each arm of the study. Treatment Procedure and Strategies: The selected patients will go through the first visit (selection - V0), when the inclusion and exclusion criteria will be evaluated. If these criteria are met, the informed consent form (ICF) will then be presented and clarified. After all doubts are resolved, the patient or his or her legal representative must sign it. In this selection visit, the baseline tests that make up the inclusion/exclusion criteria (biochemical profile and echocardiogram) will be requested. Two weeks later, on visit 1 (randomization - V1), the tests performed will be analyzed and, if the patients' eligibility is confirmed, the patients will be randomized for each arm of the study. At this visit, baseline exams for the study (Holter, 6-minute walk test and pre-defined biomarkers) will be required. After two weeks, on visit 2 (V2) a new clinical evaluation will be carried out, and with no clinical exclusion criteria (pre-defined blood pressure levels and creatinine clearance), patients will receive the study medication. After two weeks, on visit 3 (V3), a new clinical evaluation will be carried out and the medication will be titrated according to that clinical evaluation. After 2 weeks, on visit 4 (V4), a new clinical evaluation and titration, if possible, will be conducted. After 4 weeks, on visit 5 (V5), a new clinical and biochemical assessment will be carried out, in addition to titration of the medication according to blood pressure levels. After 8 weeks on visit 6 (V6), clinical evaluation and medication titration will be performed according to blood pressure levels. Finally, after another 8 weeks, on visit 7 (V7), a new clinical and biochemical evaluation will be performed, in addition to a 6-minute walk test, transthoracic echocardiography, Holter and biomarker collection. Therefore, the study will be followed up for 6 months. Withdrawal and discontinuation: Despite the limited duration of the study, participants have the right to withdraw from the clinical investigation at any time and for any reason, without prejudice to their care. Doppler Echocardiography: All patients will undergo two-dimensional echocardiography with tissue Doppler, at the beginning and at the end of the protocol, under the guidelines of the cut and image plans published by the American Society of Echocardiography. Based on this guideline, the measurements of the left ventricular (LV) systolic and diastolic diameters will be quantified, as well as their respective volumes. The thickness of the LV interventricular septum and posterior wall will also be assessed and the LV ejection fraction will be quantified by the Simpsons method. The diastolic function will be measured using the transmitral Doppler obtaining the E (initial) and A (late) waves, E / A ratio and the E wave deceleration time (DT). The investigators will also obtain the tissue Doppler traces in the basal region of the septum and in the mitral lateral ring, to analyze the velocities of the s', e' and a' waves. 24-hour Holter: All patients in the study will undergo a 24-hour Holter monitoring, at the beginning and end of the protocol. The minimum, average and maximum heart rates will be analyzed, as well as the number, frequency and density of ventricular extrasystoles; episodes, duration and frequency of sustained or not sustained ventricular tachycardia; and finally the number and size of breaks. 6-minute walk test: The test will be applied according to the 2002 American Thoracic Society Guidelines. Before performing the test, patients will have a rest period of at least 10 minutes. During this period, data on blood pressure, pulse oximetry, dyspnea level (Borg scale), heart and respiratory rate should be evaluated, so that the test can begin. Biochemical and hematological exams: The laboratory tests evaluated in the study will be urea, creatinine, sodium, potassium, ionized calcium, magnesium, glycemia and C-reactive protein. These exams will be collected at V0, V5 and V7. Biomarkers: The NT-proBNP (N terminal-pro brain natriuretic peptide) will be evaluated. The concentrations of IL-6 (interleukin-6), TNFα (tumor necrosis factor alfa), Galectin-3 present in the patients' serum or plasma will be measured at the beginning and at the end of the protocol, through enzymatic immunoassays (ELISA) using specific company kits R \& D Systems (Minneapolis, MN). For the analysis of microRNAs linked to inflammation and fibrosis, in the circulation, the investigators will follow the established protocol. The microRNAs selected for the study (mir-19a-3p; mir-30;mir-133 and housekeeping) synthesized by Applied Biosystems (Thermo Fisher Scientific Inc, USA) and their respective oligonucleotide sequences. Statistical Analysis: For the calculation of the sample size a few randomized studies have been conducted specifically in patients with Chagas cardiomyopathy. Most studies on heart failure do not distinguish the etiology of the disease, and therefore, all estimates assumed here consider that the expected effect based on the current literature is reflected in a similar way for chagasic patients. The PROVE-HF study (Januzzi et al., 2019) suggests that the improvement in EF in patients who receive sacubitril-valsartan is 5.2% with 95% CI (confidence interval) [4.8-5.6] at 6 months, which indicates a standard deviation of approximately 5.5% for this difference. The SOLVD (Studies of Left Ventricular Dysfunction) study (Kornstam et al., 1993) compared enalapril with placebo and showed an average improvement in EF of 3.0% in 1 year for patients in the enalapril group, with standard deviations at baseline and in 1 year similar to 5.5% from the previous study, which indicates that a standard deviation for the difference of 5.5% is also reasonable for the enalapril group. In addition, it is reasonable to assume that the effect in 6 months for the enalapril group is about half (1.5% or 2.0%), because PROVE-HF in one year had almost twice the effect (average improvement of 9.2%). In view of this, the investigators considers sample sizes for different scenarios, considering study powers of 80% and 90%, expected average differences between the improvements of the enalapril and sacubitril-valsartan groups varying from 2% to 5%, significance level of 5% for two-tailed hypotheses for a hypothesis test of comparison of proportions and 1:1 allocation (Chow et al., 2008). Because loss of follow-up (including death) is still possible, follow-up of these patients is a challenge. Including a 20% loss rate at the end of the estimate is suggested. Thus, the investigators could justify the study sample size of 182 (152 + \~ 20%) to identify an average difference of 2.5% of the improvement in EF with a standard deviation of 5.5%, considering a significance level of 5%, allocation 1:1, loss of follow-up of 20% and power of 80%. Statistical analysis: The normality of the quantitative variables will be assessed with the Shapiro-Wilks test. Parametric variables will be described as mean and standard deviation and compared using the Student t test. Nonparametric variables will be described with median and interquartile range and compared using the Mann-Whitney test. Categorical variables will be assessed using the chi-square test or Fisher exact test or likelihood ratio.Compliance Rules and Regulations: The protocol, the informed consent form and other documents related to the study was submitted to the Ethics Committee (CEP)/Institutional Review Board (CRI). The study will be carried out in accordance with the Declaration of Helsinki and Good Clinical Practice (GCP). Data storage and Quality Assurance and Management: It is expected that all data entered in REDCAP will have source documentation available. Data collection will be performed through an electronic case report form (eCRF).

03

Conditions studied

  • Chagas Cardiomyopathy

Keywords

  • Heart Failure
  • Chagas Disease
  • Chagas Cardiomyopathy
  • Sacubitril/Valsartan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Positive serology for Chagas;
  2. Age > 18 years old;
  3. (NYHA) heart failure and functional class II, III or IV;
  4. \<40% at least in the last 3 months;
  5. Patients using a beta-blocker with stable dose (last 4 weeks) and optimized;
  6. Patients using ACEI or ARB with a stable dose (last 4 weeks) and optimized.

Exclusion criteria

Exclusion Criteria:

  1. Participants who do not agree to participate in the study
  2. Participants who do not want to receive sacubitril/ valsartan medication;
  3. Patients with symptomatic hypotension;
  4. Patients with systolic blood pressure (SBP) lower than 95 mmHg on randomization;
  5. Patients with (ClCr) less than 30 mL/min;
  6. Patients with serum potassium > 5.2 mmol/L;
  7. Patients with a history of angioedema or who experienced severe side effects with ACE inhibitors.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Sacubitril/Valsartan

    100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan.

    Drug: Sacubitril / Valsartan Oral Tablet [Entresto]

  • Active comparator
    Enalapril

    100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril.

    Drug: Enalapril

Interventions

  • DrugSacubitril / Valsartan Oral Tablet [Entresto]

    100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan for 6 months.

    Also known as: Angiotensin receptor-neprilisin inhibitor (ARNI)

  • 100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril for 6 months.

    Also known as: Angiotensin converting enzyme inhibitors (ACE inhibitors)

06

What researchers measure

Primary outcomes

  1. Change of left ventricular ejection fraction (LVEF)

    The primary endpoint of the study will be studied by transthoracic echocardiography. The LVEF will be evaluated using Simpson method.

    Time frame: 6 months

  2. Win Ratio Analysis

    Hierarchical composite analysis composed of: 1. Time to cardiovascular death; 2. Time to first heart failure hospitalization; 3. Relative change in NT-proBNP from baseline to final visit; 4. Relative change in left ventricular ejection fraction from baseline to final visit

    Time frame: 6 meses

Secondary outcomes

  1. Number of premature ventricular beats

    It will be measured by 24 hour Holter counting the absolute number of premature ventricular beats.

    Time frame: 6 months

  2. Percentage of premature ventricular beats.

    It will be measured by 24 hour Holter counting the percentage of premature ventricular beats.

    Time frame: 6 months

  3. Ventricular arrhythmias density

    It will be measured by 24 hour Holter counting the non-sustained ventricular tachycardia rates.

    Time frame: 6 months

  4. Sustained ventricular tachycardia rates

    It will be measured by 24 hour Holter counting the sustained ventricular tachycardia rates.

    Time frame: 6 months

  5. New York Heart Association functional class

    This variable will be clinically evaluate during visits and will be analyzed in 6 months.

    Time frame: 6 months

  6. Ventricular remodeling - left ventricular systolic diameter

    It will be measured by echocardiography and the variable studied will be left ventricular systolic diameter

    Time frame: 6 months

  7. Ventricular remodeling - left ventricular diastolic diameter.

    It will be measured by echocardiography and the variable studied will be left ventricular diastolic diameter.

    Time frame: 6 months

  8. Ventricular remodeling - left ventricular systolic volume.

    It will be measured by echocardiography and the variable studied will be left ventricular systolic volume.

    Time frame: 6 months

  9. Ventricular remodeling - left ventricular diastolic volume

    It will be measured by echocardiography and the variable studied will be left ventricular diastolic volume.

    Time frame: 6 months

  10. Ventricular remodeling - thickness of the interventricular septum.

    It will be measured by echocardiography and the variable studied will be thickness of the interventricular septum.

    Time frame: 6 months

  11. Ventricular remodeling - thickness of the left ventricular posterior wall..

    It will be measured by echocardiography and the variable studied will be thickness of the LV posterior wall.

    Time frame: 6 months

  12. Safety biochemical biomarkers - urea.

    This evaluation will analyse blood urea (mg/dL).

    Time frame: 3 and 6 months

  13. Safety biochemical biomarkers - creatinine.

    This evaluation will analyse blood creatinine (mg/dL).

    Time frame: 3 and 6 months

  14. Evaluation of biomarkers - systemic cytokines.

    This evaluation will be measured using ELISA for systemic cytokines (IL-6, TNF, Galectin-3) pg/ml

    Time frame: 6 months

  15. Evaluation of biomarkers - MicroRNA.

    This evaluation will be measured using molecular biology for systemic expression for MicroRNA (MIR133, MIR19a,MIR30a)

    Time frame: 6 months

  16. Evaluation of biomarkers - NT-proBNP

    This evaluation will be measured analysing NT-proBNP (pg/ml)

    Time frame: 6 months

  17. Safety biochemical biomarkers - potassium.

    This evaluation will analyse blood potassium (mEq/L).

    Time frame: 3 and 6 months

  18. Safety biochemical biomarkers - sodium.

    This evaluation will analyse blood sodium (mEq/L).

    Time frame: 3 and 6 months

07

Study locations

1 of 1 sites recruiting
  • Heart Institute (Incor) University of Sao Paulo
    São Paulo, 05403000, Brazil
    Recruiting
    • Felix José A Ramires, MD,PhD · Contactfelix.ramires@incor.usp.br · 551126615057
    • Vagner Madrini Jr, MD · Contactvagner.madrini@incor.usp.br · 551126615057
    • Vagner Madrini Jr, MD · Sub investigator
    • Paulo Vinicius R Souza, MD · Sub investigator
    • Fabio Fernandes, MD, PhD · Sub investigator
    • Paula C Buck, PhD · Sub investigator
    • Fernanda G Pessoa, PhD · Sub investigator
    • Keila C Barbosa Fonseca, Ms, PhD · Sub investigator
    • Orlando N Ribeiro, Bch · Sub investigator
    • Cesar J Gruppi, MD, PhD · Sub investigator
    • Wilson Mathias Jr, MD, PhD · Sub investigator
    • Barbara M Ianni, MD, PhD · Sub investigator
    • Charles Mady, MD, PhD · Sub investigator
08

References and documents

Publications

  • Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet. 2009 May 2;373(9674):1570-5. doi: 10.1016/S0140-6736(09)60233-6. No abstract available. PubMed 19410718 ↗
  • Bocchi EA, Rassi S, Guimaraes GV; Argentina, Chile, and Brazil SHIFT Investigators. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial. ESC Heart Fail. 2018 Jun;5(3):249-256. doi: 10.1002/ehf2.12240. Epub 2017 Dec 20. PubMed 29266804 ↗
  • Ianni BM, Arteaga E, Frimm CC, Pereira Barretto AC, Mady C. Chagas' heart disease: evolutive evaluation of electrocardiographic and echocardiographic parameters in patients with the indeterminate form. Arq Bras Cardiol. 2001 Jul;77(1):59-62. doi: 10.1590/s0066-782x2001000700006. PubMed 11500748 ↗
  • Araujo FG, Chiari E, Dias JC. Demonstration of Trypanosoma cruzi antigen in serum from patients with Chagas' disease. Lancet. 1981 Jan 31;1(8214):246-9. doi: 10.1016/s0140-6736(81)92088-2. PubMed 6109902 ↗
  • Carod-Artal FJ, Gascon J. Chagas disease and stroke. Lancet Neurol. 2010 May;9(5):533-42. doi: 10.1016/S1474-4422(10)70042-9. PubMed 20398860 ↗
  • Barretto AC, Higuchi ML, da Luz PL, Lopes EA, Bellotti G, Mady C, Stolf N, Arteaga-Fernandez E, Pileggi F. [Comparison of histologic changes in Chagas' cardiomyopathy and dilated cardiomyopathy]. Arq Bras Cardiol. 1989 Feb;52(2):79-83. Portuguese. PubMed 2596992 ↗
  • Mady C, Cardoso RH, Barretto AC, da Luz PL, Bellotti G, Pileggi F. Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy. Circulation. 1994 Dec;90(6):3098-102. doi: 10.1161/01.cir.90.6.3098. PubMed 7994859 ↗
  • Shen L, Ramires F, Martinez F, Bodanese LC, Echeverria LE, Gomez EA, Abraham WT, Dickstein K, Kober L, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Jhund PS, Gimpelewicz CR, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators and Committees. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017 Nov;10(11):e004361. doi: 10.1161/CIRCHEARTFAILURE.117.004361. PubMed 29141857 ↗
  • McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. PubMed 25176015 ↗
  • Ramires FJA, Martinez F, Gomez EA, Demacq C, Gimpelewicz CR, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et al. ESC Heart Fail. 2018 Dec;5(6):1069-1071. doi: 10.1002/ehf2.12355. Epub 2018 Oct 9. No abstract available. PubMed 30298996 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2021 (actual). Primary completion is estimated for Dec 2024, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2021
First posted
Apr 21, 2021
StartActual
May 6, 2021
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Apr 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04853758
Collaborators
InCor Heart Institute
Responsible party
FELIX JOSÉ ALVAREZ RAMIRES (Principal Investigator, University of Sao Paulo General Hospital) — Principal investigator
First posted
Apr 21, 2021
Start date
May 6, 2021
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Apr 4, 2024

Study contacts

Felix José A Ramires, MD, PhD
Contact
felix.ramires@incor.usp.br
551126615057
Vagner Madrini Junior, MD
Contact
vagner.madrini@hotmail.com
1126615057
Felix José JA Ramires, MD,PhD
principal investigator · Instituto do Coração - INCORHCFMUSP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enalapril

Start the discussion